

Technology appraisal (TA)	Date of TA Release	Adherence of local formulary to NICE	
		Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
<b>2024-25</b>			
<a href="#">TA963 - Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency</a>	03/04/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA964 - Cabozantinib with nivolumab for untreated advanced renal cell carcinoma</a>	10/04/2024	Yes	
<a href="#">TA965 - Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)</a>	28/03/2024	No	Terminated appraisal
<a href="#">TA966 - Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)</a>	24/04/2024	No	Terminated appraisal
<a href="#">TA967 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over</a>	01/05/2024	Yes	
<a href="#">TA968 - Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	25/04/2024	No	Terminated appraisal
<a href="#">TA969 - Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)</a>	30/04/2024	No	Terminated appraisal
<a href="#">TA970 - Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments</a>	08/05/2024	Yes	
<a href="#">TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19</a>	08/05/2024	Yes	
<a href="#">TA972 - Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)</a>	22/05/2024	No	Terminated appraisal
<a href="#">TA973 - Atogepant for preventing migraine</a>	15/05/2024	Yes	
<a href="#">TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma</a>	15/05/2024	Yes	
<a href="#">TA975 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under</a>	15/05/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA976 - Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)</a>	29/05/2024	No	Terminated appraisal
<a href="#">TA977 - Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over</a>	29/05/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA978 - Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)</a>	29/05/2024	No	Terminated appraisal
<a href="#">TA979 - Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation</a>	05/06/2024	Yes	
<a href="#">TA980 - Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)</a>	05/06/2024	No	Terminated appraisal
<a href="#">TA981 - Voxelotor for treating haemolytic anaemia caused by sickle cell disease</a>	12/06/2024	No	Withdrawn from UK market in Sept 2024
<a href="#">TA982 - Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)</a>	13/06/2024	No	Terminated appraisal

<a href="#">TA983 - Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma</a>	12/06/2024	No	Not recommended
<a href="#">TA984 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy</a>	19/06/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA985 - Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma</a>	03/07/2024	No	Radiotherapy
<a href="#">TA986 - Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over</a>	10/07/2024	Yes	
<a href="#">TA987 - Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)</a>	10/07/2024	No	Terminated appraisal
<a href="#">TA988 - Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis</a>	24/07/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA989 - Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B</a>	24/07/2024	No	
<a href="#">TA990 - Tenecteplase for treating acute ischaemic stroke</a>	24/07/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA991 - Abaloparatide for treating osteoporosis after menopause</a>	07/08/2024	Yes	
<a href="#">TA992 - Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy</a>	29/07/2024	No	Not recommended
<a href="#">TA993 - Burosumab for treating X-linked hypophosphataemia in adults</a>	07/08/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA994 - Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)</a>	08/08/2024	No	Terminated appraisal
<a href="#">TA995 - Relugolix for treating hormone-sensitive prostate cancer</a>	14/08/2024	Yes	
<a href="#">TA996 - Linzagolix for treating moderate to severe symptoms of uterine fibroids</a>	14/08/2024	Yes	
<a href="#">TA997 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma</a>	29/08/2024	Yes	
<a href="#">TA998 - Risankizumab for treating moderately to severely active ulcerative colitis</a>	22/08/2024	Yes	
<a href="#">TA999 - Vibegron for treating symptoms of overactive bladder syndrome</a>	04/09/2024	Yes	
<a href="#">TA1000 - Iptacopan for treating paroxysmal nocturnal haemoglobinuria</a>	04/09/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1001 - Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment</a>	04/09/2024	Yes	

<a href="#">TA1002 - Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over</a>	11/09/2024	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA1003 - Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over</a>	11/09/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1004 - Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion</a>	11/09/2024	Yes	
<a href="#">TA1005 - Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement</a>	11/09/2024	Yes	
<a href="#">TA1006 - Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)</a>	12/09/2024	No	Terminated appraisal
<a href="#">TA1007 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</a>	17/09/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1008 - Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments</a>	25/09/2024	Yes	
<a href="#">TA1009 - Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension</a>	02/10/2024	Yes	
<a href="#">TA1010 - Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria</a>	23/10/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1011 - Belzutifan for treating tumours associated with von Hippel-Lindau disease</a>	16/10/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1012 - Avapritinib for treating advanced systemic mastocytosis</a>	06/11/2024	Yes	
<a href="#">TA1013 - Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia</a>	23/10/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1014 - Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer</a>	13/11/2024	Yes	
<a href="#">TA1015 - Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments</a>	13/11/2024	Yes	
<a href="#">TA1016 - Elafibranor for previously treated primary biliary cholangitis</a>	14/11/2024	No	CWFT is not a commissioned site
<a href="#">TA1017 - Pembrolizumab with chemotherapy before surgery (neoadjuvant), then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer</a>	20/11/2024	Yes	
<a href="#">TA1018 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis</a>	20/11/2024	Yes	
<a href="#">TA1019 - Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over</a>	20/11/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1020 - Eplontersen for treating hereditary transthyretin-related amyloidosis</a>	27/11/2024	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site

<a href="#">TA1021- Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer</a>	04/12/2024	Yes	
<a href="#">TA1022 - Bevacizumab gamma for treating wet age-related macular degeneration</a>	04/12/2024	Yes	
<a href="#">TA1023 - Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments</a>	11/12/2024	Yes	
<a href="#">TA1024 - Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)</a>	11/12/2024	No	Terminated appraisal
<a href="#">TA1025 - Ublituximab for treating relapsing multiple sclerosis</a>	18/12/2024	Yes	
<a href="#">TA1026 - Tirzepatide for managing overweight and obesity</a>	23/12/2024	Yes	
<a href="#">TA1027 - Tebentafusp for treating advanced uveal melanoma</a>	09/01/2024	Yes	
<a href="#">TA1028 - Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)</a>	15/01/2025	No	Terminated appraisal
<a href="#">TA1029 - Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)</a>	15/01/2025	No	Terminated appraisal
<a href="#">TA1030 - Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer</a>	15/01/2025	Yes	
<a href="#">TA1031 - Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over</a>	16/01/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1032 - Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)</a>	22/01/2025	No	Terminated appraisal
<a href="#">TA1033 - Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over</a>	12/02/2025	No	Not recommended
<a href="#">TA1034 - Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours</a>	22/01/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1035 - Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease</a>	23/01/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1036 - Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment</a>	05/02/2025	Yes	
<a href="#">TA1037 - Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer</a>	05/02/2025	Yes	
<a href="#">TA1038 - Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over</a>	12/02/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1039 - Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over</a>	12/02/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site

<a href="#">TA1040 - Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy</a>	12/02/2025	Yes	
<a href="#">TA1041 - Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer</a>	19/02/2025	Yes	
<a href="#">TA1042 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer</a>	19/02/2025	Yes	
<a href="#">TA1043 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection</a>	26/02/2025	Yes	
<a href="#">TA1044 - Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over</a>	26/02/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1045 - 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites</a>	05/03/2025	Yes	
<a href="#">TA1046 - Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma</a>	12/03/2025	No	Not recommended
<a href="#">TA1047 - Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)</a>	12/03/2025	No	Terminated appraisal
<a href="#">TA1048 - Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable</a>	26/03/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1049 - Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia</a>	26/03/2025	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA1050 - Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over</a>	26/03/2025	Yes	